PRNP M129V homozygosity in multiple system atrophy vs. Parkinson’s disease
Tóm tắt
Multiple system atrophy (MSA) is a neurodegenerative disorder of unknown etiology characterized by extrapyramidal, pyramidal, cerebellar, and autonomic dysfunction in any combination. We report a patient with a 4-year history of MSA who developed dementia associated with sporadic Creutzfeldt–Jakob disease (CJD). Our proband was MM homozygous for the M129V polymorphism within the prion protein gene (PRNP), a known risk factor for CJD. We conducted a case–control study to test the hypothesis that homozygosity for the M129V polymorphism of PRNP occurs more frequently in MSA in comparison to Parkinson’s disease and healthy volunteers. A total of 63 patients with MSA, 54 age-, race- and gendermatched controls with Parkinson’s disease, and 126 matched healthy volunteers were studied. The genotype analysis revealed no significant difference in the codon 129 genotype distribution in MSA as compared to controls. Nonetheless, the frequencies of the MM and VV genotypes were higher in MSA than in Parkinson’s disease. Thus, homozygosity, particularly VV homozygosity, at codon 129 of PRNP is associated with MSA compared to a clinically related but pathophysiologically distinct α-synucleinopathy. Considering the possibility that the prion protein contributes to the pathogenesis of MSA would require confirmation of these findings in an independent patient population.
Tài liệu tham khảo
Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro CJ, Hegyi I, Collins S, Kretzschmar H, van Duijn C, Will RG (1999) Codon 129 prion protein genotype and sporadic Creutzfeldt–Jakob disease. Lancet 353:1673–1674
Berr C, Richard F, Dufouil C, Amant C, Alperovitch A, Amouyel P (1998) Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study. Neurol 51:734–737
Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM (1999) Normal prion protein has an activity like that of superoxide dismutase. Biochem J 344 (Pt 1):1–5
Brown P, Cervenakova L, Goldfarb LG, McCombie WR, Rubenstein R, Will RG, Pocchiari M, Martinez-Lage JF, Scalici C, Masullo C (1994) Iatrogenic Creutzfeldt–Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurol 44:291–293
Cervenakova L, Goldfarb LG, Garruto R, Lee HS, Gajdusek DC, Brown P (1998) Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt–Jakob disease. Proc Natl Acad Sci USA 95:13239–13241
Collinge J, Harding AE, Owen F, Poulter M, Lofthouse R, Boughey AM, Shah T, Crow TJ (1989) Diagnosis of Gerstmann–Straussler syndrome in familial dementia with prion protein gene analysis. Lancet 2:15–17
Combarros O, Infante J, Llorca J, Berciano J (2003) Interleukin-1A (-889) genetic polymorphism increases the risk of multiple system atrophy. Mov Disord 18:1385–1386
Furiya Y, Hirano M, Kurumatani N, Nakamuro T, Matsumura R, Futamura N, Ueno S (2005) Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA). Brain Res Mol Brain Res 138:178–181
Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985–989
Gilman S, Low P, Quinn N, Albanese A, Ben Shlomo Y, Fowler C, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning G (1998) Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Autonomic Res 8:359–362
Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501
Gossrau G, Herting B, Mockel S, Kempe A, Koch R, Reichmann H, Lampe JB (2006) Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson’s disease. J Neural Transm 113:331–337
Haik S, Privat N, Adjou KT, Sazdovitch V, Dormont D, Duyckaerts C, Hauw JJ (2002) Alpha-synuclein-immunoreactive deposits in human and animal prion diseases. Acta Neuropathol (Berl) 103:516–520
Healy DG, Abou-Sleiman PM, Quinn N, Ahmadi KR, Ozawa T, Kamm C, Wullner U, Oertel WH, Burk K, Dupont E, Pellecchia MT, Tolosa E, Gasser T, Holton JL, Revesz T, Goldstein DB, Lees AJ, Wood NW (2005) UCHL-1 gene in multiple system atrophy: a haplotype tagging approach. Mov Disord 20:1338–1343
Infante J, Llorca J, Berciano J, Combarros O (2005) Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy. J Neurol Sci 228:11–13
Jendroska K, Hoffmann O, Schelosky L, Lees AJ, Poewe W, Daniel SE (1994) Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson’s syndrome. J Neurol Neurosurg Psychiatry 57:1249–1251
Johnson MD, Vnencak-Jones CL, McLean MJ (1998) Fatal familial insomnia: clinical and pathologic heterogeneity in genetic half brothers. Neurol 51:1715–1717
Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, Budka H (2002) Mutations of the prion protein gene phenotypic spectrum. J Neurol 249:1567–1582
Kovacs GG, Voigtlander T, Gelpi E, Budka H (2004) Rationale for diagnosing human prion disease. World J Biol Psychiatry 5:83–91
Kretzschmar HA, Prusiner SB, Stowring LE, DeArmond SJ (1986) Scrapie prion proteins are synthesized in neurons. Am J Pathol 122:1–5
Lampe J, Kitzler H, Walter MC, Lochmuller H, Reichmann H (1999) Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet 353:465–466
Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, Schellenberg GD, Peskind E, Johnson N, Siddique T, Mesulam MM, Weintraub S, Mastrianni JA (2005) Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol 58:858–864
Mead S (2006) Prion disease genetics. Eur J Hum Genet 14:273–281
Medori R, Tritschler HJ, LeBlanc A, Villare F, Manetto V, Chen HY, Xue R, Leal S, Montagna P, Cortelli P (1992) Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 326:444–449
Morris HR, Vaughan JR, Datta SR, Bandopadhyay R, Rohan De Silva HA, Schrag A, Cairns NJ, Burn D, Nath U, Lantos PL, Daniel S, Lees AJ, Quinn NP, Wood NW (2000) Multiple system atrophy/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. Neurol 55:1918–1920
Nishimura M, Kuno S, Kaji R, Kawakami H (2005) Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy. Neurosci Lett 374:218–221
Palmer MS, Dryden AJ, Hughes JT, Collinge J (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt–Jakob disease. Nature 352:340–342
Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AA, Trojanowski JQ, Petersen RB, Gambetti P (1996) Molecular basis of phenotypic variability in sporadic Creutzfeldt–Jakob disease. Ann Neurol 39:767–778
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
Rachidi W, Mange A, Senator A, Guiraud P, Riondel J, Benboubetra M, Favier A, Lehmann S (2003) Prion infection impairs copper binding of cultured cells. J Biol Chem 278:14595–14598
Rachidi W, Vilette D, Guiraud P, Arlotto M, Riondel J, Laude H, Lehmann S, Favier A (2003) Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery. J Biol Chem 278:9064–9072
Roucou X, Gains M, LeBlanc AC (2004) Neuroprotective functions of prion protein. J Neurosci Res 75:153–161
Scholz SW, Xiromerisiou G, Fung HC, Eerola J, Hellstrom O, Papadimitriou A, Hadjigeorgiou GM, Tienari PJ, Fernandez HH, Mandel R, Okun MS, Gwinn-Hardy K, Singleton AB (2005) The human prion gene M129V polymorphism is not associated with idiopathic Parkinson’s disease in three distinct populations. Neurosci Lett 395(3):227–229
Shibao C, Gamboa A, Diedrich A, Biaggioni I (2005) Management of hypertension in the setting of autonomic failure. A pathophysiological approach. Hypertension 45(4):469–476
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302–305
Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344–18349
Tranchant C, Geranton L, Guiraud-Chaumeil C, Mohr M, Warter JM (1999) Basis of phenotypic variability in sporadic Creutzfeldt–Jakob disease. Neurol 52:1244–1249
Wong BS, Chen SG, Colucci M, Xie Z, Pan T, Liu T, Li R, Gambetti P, Sy MS, Brown DR (2001) Aberrant metal binding by prion protein in human prion disease. J Neurochem 78:1400–1408